Brief: Gri Bio (Nasdaq Gri) Announces Board Of Director Appointments Adding Leadership And Expertise Spanning A Combined 75 Years In Both Public And Private Sectors In The Life Sciences Industry
Brief: Vallon Pharmaceuticals Announces Stockholder Approval Of Merger With Gri Bio And Reverse Stock Split
Brief: Vallon Pharmaceuticals Inc - On Feb 28, Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
U.S. STOCKS ON THE MOVE-Meta, Bed Bath & Beyond
U.S. STOCKS ON THE MOVE-Pfizer, Harrow Health, Vallon Pharma
Vallon Pharma skyrockets on merger with GRI Biotech
Vallon Pharma gains on merger agreement with GRI Bio
Brief: Vallon Pharmaceuticals And Gri Bio Enter Into Merger Agreement With Goal Of Advancing Innovative Pipeline Of Nkt Cell Regulators
Brief: Vallon Pharmaceuticals Reports Third Quarter 2022 Results
Brief: Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results
Brief: Vallon Pharmaceuticals- On June 27 Co Got Notice From Nasdaq Indicating Co No Longer Complies With The Minimum Bid Price Requirement
Brief: Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering
Brief: Vallon Pharmaceuticals Reports Additional Pharmacokinetic And Pharmacodynamic Data From SEAL Study Of ADAIR
Vallon Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Vallon Pharmaceuticals Announces Issuance Of Japanese Patent Covering Composition Of Matter And Methods Of Manufacturing For ADAIR
Brief: Vallon Pharmaceuticals Inc Files For Mixed Shelf Of Up To $75 Million - SEC Filing
Vallon Pharma more than doubles on strategic review
Vallon Pharma soars on strategic review
Brief: Vallon Streamlines Operations To Preserve Capital, Cash Resources